ATAI Life Sciences N.V (NASDAQ:ATAI) has a beta value of 1.22 and has seen 2.59 million shares traded in the last trading session. The company, currently valued at $293.66M, closed the last trade at $1.75 per share which meant it lost -$0.03 on the day or -1.69% during that session. The ATAI stock price is -62.86% off its 52-week high price of $2.85 and 41.14% above the 52-week low of $1.03. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.13 million shares traded. The 3-month trading volume is 1.57 million shares.
The consensus among analysts is that ATAI Life Sciences N.V (ATAI) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
Sporting -1.69% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ATAI stock price touched $1.75 or saw a rise of 8.38%. Year-to-date, ATAI Life Sciences N.V shares have moved 31.58%, while the 5-day performance has seen it change 29.63%. Over the past 30 days, the shares of ATAI Life Sciences N.V (NASDAQ:ATAI) have changed 17.45%. Short interest in the company has seen 10.61 million shares shorted with days to cover at 5.49.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 70.83% from current levels. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the current price level is -242.86% off the targeted high while a plunge would see the stock gain -242.86% from current levels.
ATAI Life Sciences N.V (ATAI) estimates and forecasts
Figures show that ATAI Life Sciences N.V shares have underperformed across the wider relevant industry. The company’s shares have gained 32.58% over the past 6 months, with this year growth rate of -208.00%, compared to 14.30% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 44.19% over the past 5 years.
ATAI Dividends
ATAI Life Sciences N.V is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ATAI Life Sciences N.V (NASDAQ:ATAI)’s Major holders
Insiders own 9.99% of the company shares, while shares held by institutions stand at 26.76% with a share float percentage of 29.73%. Investors are also buoyed by the number of investors in a company, with ATAI Life Sciences N.V having a total of 104.0 institutions that hold shares in the company. The top two institutional holders are WALLEYE CAPITAL LLC with over 2.76 million shares worth more than $3.67 million. As of 2024-06-30, WALLEYE CAPITAL LLC held 1.7388% of shares outstanding.
The other major institutional holder is MORGAN STANLEY, with the holding of over 2.72 million shares as of 2024-06-30. The firm’s total holdings are worth over $3.62 million and represent 1.7111% of shares outstanding.
